Investees
Investees
We were delighted to welcome the following investees. The company profiles are listed in alphabetical order from A-Z. Click on the company logo to jump to the information.
AlphaRET
AlphaRET Pty Ltd is a wholly owned subsidiary of Nova Eye Medical Limited. AlphaRET Pty Ltd is a special purpose entity established to commercialise 2RT®, a nano-pulse ophthalmic laser technology that is a breakthrough treatment for Age related Macular Degeneration (AMD).
Cyban
Cyban is advancing the way brain injuries are detected and managed.
Our mission is to change the standard of care in how brain injuries are detected and managed by providing cutting edge solutions to enhance clinical decision making.
Our Brain Pulse Monitor provides non-invasive, continuous measures of intracranial pressure, oxygen saturation and cerebral perfusion that are accurate relative to the existing “gold standard” invasive probes.
The Brain Pulse Monitor enables early detection and treatment of brain hypoxia for unconscious and intubated patients in Intensive Care Units and the Operating Theatre.
We help clinicians:
minimise the likelihood of misjudging the risk of brain tissue injury.
minimise the time it takes to determine how the brain injury will impact the treatment being considered or provided.
minimise the risk of further brain injury and infection inherit in the current invasive monitoring standard of care.
reduce the cost of care in high value ICU and Operating Theatre settings.
Fusetec
Fusetec was founded in 2017, to answer the research question, ‘’How Do Surgeon’s Train.’’ Their mission is to improve healthcare outcomes by providing safe, affordable, and effective training alternatives to upskill residents and continually advance surgeon training.
The use of cadavers in surgical training is high risk, potentially infectious, highly regulated, costly and with limited access to pathology.
Fusetec is an IP centric company for the purposes of commercial activities they advance manufactures anatomically accurate, fully operable, surgical training models with pathology for surgical simulation training while disrupting the cadaver market and exports their products globally.
Fusetec’s journey is just beginning.
LBT Innovations
LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT’s wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases.
OncoRes Medical
OncoRes Medical is on a mission is to revolutionise cancer surgery.
Complete surgical clearance is the foundation of curative cancer treatment for the 17 million patients globally diagnosed with a solid cancer each year. But, there are currently no accurate and easy to use technologies for surgeons to identify residual cancer remaining inside the patient during surgery, meaning a high proportion of patients will have cancer left behind.
OncoRes Medical is a clinical-stage company developing a category-defining digital imaging system for real-time cancer detection to guide precision surgical cancer clearance, starting with Breast Conserving Surgery. Our QME (Quantitative Micro-Elastography) Imaging system is designed by surgeons, for surgeons – a highly differentiated solution that fits seamlessly into surgical workflow, is simple to learn and use. It enables a new standard of care by providing information in real-time to surgeons about what remains inside the patient. QME is a novel, propriety technology that generates quantitative, 3D imaging data and measures micro-scale tissue stiffness.
TekCyte
TekCyte was incorporated in May 2018 as a spin out of the CRC for Cell Therapy Manufacturing. It is a B2B enterprise developing novel nano-scale coatings that can improve the safety and performance of medical devices. Our coatings have been developed specifically for biological applications where biomaterials including implantable devices come in direct contact with blood, cells and/or tissue. The company’s main focus is on biofilm-resistant coatings to help reduce the incidence of infection associated with implantable devices. TekCyte aims to partner with leading device manufacturers seeking to improve the performance and safety of their medical device products.
Vaxxas
Vaxxas is a privately held, Australian-based biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious diseases and oncology.
To date, the company has had success in several clinical trials involving more than 500 participants including Phase I clinical studies for COVID-19, seasonal influenza and measles and rubella. In 2024, it will begin a Phase I study for pandemic influenza funded by the United States Government’s Biomedical Advanced Research and Development Authority (BARDA).
The company opened its global headquarters and first manufacturing facility in Brisbane in June 2023 with support from the Queensland government. From this site, Vaxxas is advancing toward first commercial products in the next three – five years.
Wellumio
Wellumio is a medical technology startup developing an ultra-portable MRI scanner (Axana) with a primary focus on early diagnostic triage for acute stroke, a leading cause of human mortality and disability. Co-founded in 2019 and led by co-CEOs Dr Shieak Tzeng and Dr Sergei Obruchkov, the company’s mission is to advance the availability and affordability of point-of-care imaging. Wellumio's second-generation scanner, Axana, achieves a 99% weight reduction compared to conventional MRI, establishing it as the most portable imaging system in the global USD15B mobile imaging services market.
